resulted in reduced tumor growth, invasion, and metastases. PF-562,271 had no effect on tumor necrosis, angiogenesis or apoptosis, but did decrease tumor cell proliferation and resulted in fewer tumor-associated macrophages and fibroblasts compared to control or gemcitabine. These data support a role for FAK in PDA and suggest that inhibitors of FAK may contribute to efficacious treatment of patients with PDA.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) remains the 4 th leading cause of cancer-related deaths in the United States (1) . Current cytotoxic therapies (gemcitabine, 5-fluorouracil, and oxaliplatin) and anti-EGF therapy (erlotinib) provide only modest improvement in overall survival (2) (3) (4) (5) (6) .
PDA is characterized by aggressive locoregional invasion and early metastasis, indicating a central role for signaling pathways that regulate cell migration. Additionally, PDA typically evokes a desmoplastic reaction characterized by significant invasion and proliferation of stromal cancerassociated fibroblasts (myofibroblasts-stellate cells) and deposition of extracellular matrix (ECM) proteins (7) .
Focal adhesion kinase (FAK), a nonreceptor cytoplasmic protein tyrosine kinase, is a key regulator of signals from the ECM mediated by integrins and growth factor receptors (8) . FAK has been implicated in the regulation of a variety of cellular signaling pathways that control cell proliferation, cell cycle progression, migration, apoptosis, and cell survival (9) (10) (11) (12) . Expression of FAK is reported to be upregulated in many tumor types including colon, breast, prostate, thyroid, head and neck, liver, and esophageal (12) (13) (14) (15) (16) (17) , and elevated expression of FAK correlates with poor survival rates (17, 18) . In PDA, it has been reported that increased FAK expression correlates with tumor size (19) . Gene silencing of FAK by RNA interference resulted in suppression of anoikis resistance and metastasis in a preclinical model of PDA (20) . Several small molecule inhibitors 4 of FAK have been described, most notably PF-562,271 a potent small molecule inhibitor of FAK and the related tyrosine kinase, PYK2 (21) . PF-562,271 is reported to be efficacious in inhibiting the proliferation of tumors in both xenograft and transgenic mouse models (22, 23) Because of the prominent role of the microenvironment in the progression and metastasis of PDA, we undertook to determine the role of FAK/PYK2 catalytic activity in the proliferation and migration of tumor cells, and stromaassociated cells (macrophages and pancreatic stellate cells), the latter cells that populate the tumor microenvironment and contribute to the desmoplastic response of PDA. We show that chemotactic (IGF-I and EGF) and haptotactic 
generously provided by Pfizer, Inc. (La Jolla, CA), is a potent ATP-competitive reversible inhibitor selective for recombinant FAK and PYK2 kinase with an IC 50 of 1.5 nM and 14 nM, respectively (21, 22) . Animals were treated with PF-562,271 at 33 mg/kg body weight twice per day as described previously (22, 23) .
Gemcitabine (2′,2′-difluoro-2′-deoxycytidine) was given 10 mg/kg i.p. twice per week as described previously (27) .
Western blot and receptor tyrosine kinase arrays.
Cultured cells were lysed and subjected to Western blotting for FAK, PYK2, phospho-FAK (pY397), and phospho-PYK2 (pY402) as described previously (28). Human Phospho-Receptor Tyrosine Kinase (pRTK) Arrays (R&D Systems, Minneapolis, MN) were used to evaluate the pRTK signature in PDA cell lines per manufacturer's protocol. Transwell migration, invasion and proliferation assays.
Cell migration and invasion assays were performed using transwell migration chambers (BD Biosciences, Bedford, MA) as previously described (26) (27) (28) . Conditioned media was prepared from subconfluent MPanc-96 or MAD08-608 cells by harvesting growth medium (containing 0.5% FBS) for two 24 h periods. The conditioned media was centrifuged to remove cellular debris and Student's t test was used to determine the significance of difference in the mean values and Fisher's exact test to calculate the significance of difference between categorical variables. Significance was determined with 95% confidence.
RESULTS

FAK/PYK2 in pancreatic cancers
FAK and the related protein PYK2 are well studied regulators of cell adhesion signaling and migration (29) . To better understand the role of FAK/PYK2 signaling in both PDA and stromal cell migration we have examined MPanc-96 and MAD08-608 PDA cells, macrophages and HPSCs (25) . Immunohistochemical staining of normal pancreas and PDA with an antibody to FAK revealed strong staining for FAK throughout the PDA sections with staining most intense in the malignant ductal cells (Fig. 1B) . In contrast, weaker staining of normal pancreatic tissue for FAK expression was observed (Fig. 1B) . Using Western immunoblotting, FAK and PYK2 expression were readily observed in both MPanc-96 and MAD08-608 cells as well as several other PDA cell lines and cultured HPSCs (Fig. 1C) . In all cases, FAK and PYK2 were activated as evidenced by tyrosine phosphorylation of FAK397Y and PYK402Y (Fig. 1C) .
To evaluate the effects of PF-562,271 on FAK activity, MPanc-96 and MAD08-608 cells were incubated PF-562,271, and FAK activity was assessed by immunoblotting extracts with an antibody to FAK phospho-Y397. As shown in Since activated EGF and insulin/IGF family receptors were expressed in both MPanc-96 and MAD08-608 cells, we evaluated the effects of PF-562,271 on growth factor-mediated cell migration. In MPanc-96 cells, IGF-I (100 ng/mL) significantly stimulated cell migration (Fig. 3A) and treatment of MPanc-96 cells with 0.1 μM PF-562,271 resulted in a significant decrease in migration compared to IGF-I stimulation alone (Fig. 3A) . EGF also stimulated migration, but interestingly, the observed migration was insensitive to addition of PF-562,271.
Because of the increased deposition of ECM proteins (e.g. Col-I) in PDA, we evaluated the ability of PF-562,271 to inhibit haptotactic migration. Col-I stimulated migration of both MPanc-96 (Fig. 3A) and MAD08-608 cells (supplemental data). Pretreatment of either cell line with PF-562,271 (0.1 μM) led to a significant reduction in haptotactic migration (Fig. 3A) . Perineural, lymphovascular, and extrapancreatic invasion are common histologic characteristics of PDA and associated with worse prognosis. To assess the invasive activities of MPanc-96 and MAD08-608 cells, assays were performed as above, but with Matrigel inserts. Serum stimulated invasion in both cell types and pretreatment with 0.1 μM of PF-562,271 significantly inhibited invasion (Fig. 3A and supplemental data). These data illustrate that migration and invasion of MPanc-96 and MAD08-608 cells are dependent to some degree on the catalytic activity of FAK and/or PYK2. that seen with the macrophages (Fig. 5B and supplemental data) . Treatment of mice with gemcitabine also led to no change or a slight increase in fibroblasts within the tumor compared to control, while treatment with PF-562,271 yielded significantly fewer fibroblasts as a single agent compared to control. (Fig. 5B and   supplemental 
